Rigor Equity Announces 163-Unit Ground-Up Multifamily Development in High-Growth Madison Market
CHICAGO, IL / ACCESS Newswire / April 1, 2026 / Rigor Equity is leading the
CHICAGO, IL / ACCESS Newswire / April 1, 2026 / Rigor Equity is leading the
WOBURN, MA / ACCESS Newswire / April 1, 2026 / Bridgeline Digital, Inc. (NASDAQ:BLIN), a
Filers can electronically file Form 941 for the first quarter of 2026 through TaxBandits as
MPS Law continues strategic growth in land use, zoning and entitlement with the addition of
Audited Annual Financial Statements Released in Australia and Canada Highlights Temas has secured multiple third-party
NEW YORK, NY / ACCESS Newswire / April 1, 2026 / Ares Capital Corporation (“Ares
TORONTO, ON / ACCESS Newswire / April 1, 2026 / Grid Metals Corp. (TSXV:GRDM)(OTCQB:MSMGF) (“Grid”
TORONTO, ON / ACCESS Newswire / April 1, 2026 / Aclara Resources Inc. (“Aclara” or
OWC Technology Maximizes Productivity and Creativity, Protects Work, and Enables Greater Business Success Don’t Miss:
LOS ANGELES, April 1, 2026 /PRNewswire/ — Following the release of several authoritative 2025 annual
LOS ANGELES , April 1, 2026 /PRNewswire/ — KAIJU NO. 8 THE GAME, co-produced by Akatsuki
Vancouver, British Columbia–(Newsfile Corp. – March 31, 2026) – Metavista3D Inc. (TSXV: DDD) (FSE: E3T)
Gentry, Arkansas–(Newsfile Corp. – March 31, 2026) – Small business owners in Benton County and
Vienna, Austria–(Newsfile Corp. – March 31, 2026) – Felix Honigwachs has announced the launch of
Dallas ad agency’s in-house production studio rebrands, expanding production opportunities DALLAS, March 31, 2026 /PRNewswire/
BEIJING, March 31, 2026 /PRNewswire/ — iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a
BUENOS AIRES, ARGENTINA, MARCH 31, 2026 ― When the Teatro Colón opens its doors to
Creative Technology Group, Inc. (CT), the NEP Live Events group, has invested in multiple Analog
AiGS will leverage n8n’s platform to deliver future-ready automation solutions that streamline operations and unlock
First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety